{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:25:34Z","timestamp":1781375134323,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We sought to understand the clinical course and molecular phenotype of patients who showed disease progression after programmed cell death ligand 1 (PD-L1) inhibitor treatment but subsequently responded to PD-1 inhibitor treatment.  We also explored the response to PD-1-axis targeted therapy of classical Hodgkin lymphoma (cHL) according to genetically driven PD-L1 and programmed cell death ligand 2 (PD-L2) expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>\n  Five patients in a phase II clinical trial of CS1001 (PD-L1 inhibitor) for relapsed or refractory (R\/R) cHL were retrospectively reviewed. Formalin-fixed, paraffin-embedded whole tissues from the five patients were evaluated for 9p24.1 genetic alterations based on FISH and the expression of PD-L1, PD-L2, PD-1, major histocompatibility complex (MHC) class I\u2013II, and the tumor microenvironment factorsCD163 and FOXP3 in the microenvironmental niche, as revealed by multiplex immunofluorescence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All five patients showed primary refractory disease during first-line treatment. Four patients received PD-1 inhibitor after dropping out of the clinical trial, and all demonstrated at least a partial response. The progression-free survival ranged from 7 to 28\u2009months (median = 18\u2009months), and 9p24.1 amplification was observed in all five patients at the PD-L1\/PD-L2 locus. PD-L1 and PD-L2 were colocalized on Hodgkin Reed-Sternberg (HRS) cells in four of the five (80%) patients. There was differential expression of PD-L1 and PD-L2 in cells in the tumor microenvironment in cHL, especially in HRS cells, background cells and tumor-associated macrophages.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PD-L1 monotherapy may not be sufficient to block the PD-1 pathway; PD-L2 was expressed in HRS and background cells in cHL. The immunologic function of the PD-L2 pathway in anti-tumor activity may be underestimated in R\/R cHL. Further study is needed to elucidate the anti-tumor mechanism of PD-1 inhibitor and PD-L1 inhibitor treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09028-4","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T08:06:58Z","timestamp":1641197218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed\/Refractory classical Hodgkin Lymphoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Xi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxiang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiyun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuailing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"9028_CR1","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1056\/NEJMc0906731","volume":"361","author":"GP ND Canellos","year":"2009","unstructured":"Canellos GP ND, Johnson JL: Long-Term Follow-Up Hodgkin\u2019s Lymphoma. N Engl J Med 361:2390\u201391, 2009","journal-title":"N Engl J Med"},{"key":"9028_CR2","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Ligon AH, et al: PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol 34:2690\u20137, 2016","journal-title":"J Clin Oncol"},{"key":"9028_CR3","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","volume":"130","author":"CD Carey","year":"2017","unstructured":"Carey CD, Gusenleitner D, Lipschitz M, et al: Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130:2420\u20132430, 2017","journal-title":"Blood"},{"key":"9028_CR4","doi-asserted-by":"publisher","first-page":"k3529","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen X, Zhao B: Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362:k3529, 2018","journal-title":"BMJ"},{"key":"9028_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","volume":"36","author":"MGM Roemer","year":"2018","unstructured":"Roemer MGM, Redd RA, Cader FZ, et al: Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942\u2013950, 2018","journal-title":"J Clin Oncol"},{"key":"9028_CR6","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1182\/bloodadvances.2017006346","volume":"1","author":"P Hollander","year":"2017","unstructured":"Hollander P, Kamper P, Smedby KE, et al: High proportions of PD-1(+) and PD-L1(+) leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome. Blood Adv 1:1427\u20131439, 2017","journal-title":"Blood Adv"},{"key":"9028_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","volume":"21","author":"B Geoerger","year":"2020","unstructured":"Geoerger B, Zwaan CM, Marshall LV, et al: Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. Lancet Oncol 21:134\u2013144, 2020","journal-title":"Lancet Oncol"},{"key":"9028_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311\u20139, 2015","journal-title":"N Engl J Med"},{"key":"9028_CR9","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, et al: Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol 36:1428\u20131439, 2018","journal-title":"J Clin Oncol"},{"key":"9028_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1309\/AJCP61TLMXLSLJYS","volume":"141","author":"JL Klein","year":"2014","unstructured":"Klein JL, Nguyen TT, Bien-Willner GA, et al: CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am J Clin Pathol 141:381\u20137, 2014","journal-title":"Am J Clin Pathol"},{"key":"9028_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","volume":"31","author":"P Greaves","year":"2013","unstructured":"Greaves P, Clear A, Coutinho R, et al: Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 31:256\u201362, 2013","journal-title":"J Clin Oncol"},{"key":"9028_CR12","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1111\/cas.13769","volume":"109","author":"N Oike","year":"2018","unstructured":"Oike N, Kawashima H, Ogose A, et al: Prognostic impact of the tumor immune microenvironment in synovial sarcoma. Cancer Sci 109:3043\u20133054, 2018","journal-title":"Cancer Sci"},{"key":"9028_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hon.878","volume":"27","author":"S Schreck","year":"2009","unstructured":"Schreck S, Friebel D, Buettner M, et al: Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 27:31\u20139, 2009","journal-title":"Hematol Oncol"},{"key":"9028_CR14","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","volume":"131","author":"F Vari","year":"2018","unstructured":"Vari F, Arpon D, Keane C, et al: Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 131:1809\u20131819, 2018","journal-title":"Blood"},{"key":"9028_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","volume":"71","author":"PK Panjwani","year":"2018","unstructured":"Panjwani PK, Charu V, DeLisser M, et al: Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol 71:91\u201399, 2018","journal-title":"Hum Pathol"},{"key":"9028_CR16","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, et al: Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268\u201377, 2010","journal-title":"Blood"},{"key":"9028_CR17","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","volume":"23","author":"JH Yearley","year":"2017","unstructured":"Yearley JH, Gibson C, Yu N, et al: PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res 23:3158\u20133167, 2017","journal-title":"Clin Cancer Res"},{"key":"9028_CR18","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1158\/1078-0432.CCR-18-3991","volume":"25","author":"T Tanegashima","year":"2019","unstructured":"Tanegashima T, Togashi Y, Azuma K, et al: Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clin Cancer Res 25:4808\u20134819, 2019","journal-title":"Clin Cancer Res"},{"key":"9028_CR19","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","volume":"4","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Redd RA, et al: Classical Hodgkin Lymphoma with Reduced beta2M\/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunol Res 4:910\u2013916, 2016","journal-title":"Cancer Immunol Res"},{"key":"9028_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani A, Sozzani S, Locati M, et al: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549\u201355, 2002","journal-title":"Trends Immunol"},{"key":"9028_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/978-1-60327-530-9_18","volume":"512","author":"T Hagemann","year":"2009","unstructured":"Hagemann T, Lawrence T: Investigating macrophage and malignant cell interactions in vitro. Methods Mol Biol 512:325\u201332, 2009","journal-title":"Methods Mol Biol"},{"key":"9028_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1746-1596-7-12","volume":"7","author":"JA Harris","year":"2012","unstructured":"Harris JA, Jain S, Ren Q, et al: CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 7:12, 2012","journal-title":"Diagn Pathol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09028-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09028-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09028-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T20:03:49Z","timestamp":1641240229000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09028-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9028"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09028-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"assertion":[{"value":"4 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of archived tissues in this study was approved by ethical committee of Zhejiang Cancer Hospital.  Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}